What are ADC's

Our services

ADC Review
is made possible by:

NCT01691898 (Clinical Trial / DCDT2980S / Pinatuzumab Vedotin / RG-7593)

Study Title
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin’s Lymphoma (NCT01691898)

Trial Description
This randomized, multicenter, open-label study will evaluate the safety and the efficacy of DCDT2980S (pinatuzumab vedotin or RG-7593) in combination with MabThera/Rituxan (rituximab) or DCDS4501A (polatuzumab vedotin or RG-7596) in combination with MabThera/Rituxan, as well as a combination of DCDS4501A with obinutuzumab in patients with relapsed or refractory follicular non-Hodgkin’s lymphoma and relapsed/refractory diffuse large B-cell lymphoma.

This trial is sponsored by Genentech, Inc. [1]

Study Data

  • Condition:
    • Follicular Lymphoma
    • B-Cell Lymphoma
  • Interventions:
    • Drugs used in this trial
      • DCDS4501A (polatuzumab vedotin or RG-7596; Genentech)
      • DCDT2980S (pinatuzumab vedotin or RG-7593; Genentech)
      • obinutuzumab (Gazyva®,Genentech, Inc.)
      • rituximab (Rituxam®; Biogen, Inc,/ Genentech, Inc.)
  • Phase: II
  • Estimated Enrollment: 226
  • Start: September 2012
  • Estimated Completion: June 2019
  • Last verified: July 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 13, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar